A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial

• Published in: Clinical cancer research Vol. 28; no. 22; pp. 4885 - 4892
• Main Authors: Hillemanns, Peter, Denecke, Agnieszka, Woelber, Linn, Böhmer, Gerd, Jentschke, Matthias, Schjetne, Karoline W., Bruins Slot, Karsten M.H., Fredriksen, Agnete B.
• Format: Journal Article
• Language: English
• Published: United States 14.11.2022
• Subjects: Antigen-Presenting Cells; Cancer Vaccines - adverse effects; Female; Human papillomavirus 16 - genetics; Humans; Oncogene Proteins, Viral; Papillomavirus Infections; Papillomavirus Vaccines; Uterine Cervical Dysplasia - drug therapy; Uterine Cervical Neoplasms - drug therapy; Vaccines, DNA - adverse effects

To evaluate the safety, immunogenicity and efficacy of a therapeutic DNA vaccine VB10.16, using a unique modular vaccine technology that is based on linking antigens to CCL3L1 targeting module, in women with HPV16-positive high-grade cervical intraepithelial neoplasia (CIN). We conducted a first-in-...